Affymax (AFFY) wins approval for its drug to treat anemic kidney patients -Bloomberg
Affymax (Nasdaq: AFFY) wins approval for its drug to treat anemic kidney patients
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Lexicon Pharma (LXRX) Announces TELESTAR Phase 3 Met Primary Endpoint
- Clovis Oncology (CLVS) Announces Submission of Rociletinib NDA to U.S. FDA
- Horizon Pharma (HZNP) Receives Notice of Allowance from USPTO for PENNSAID-Related Patent